News

Elevator Pitch Entrepreneurs Win $10,000 in Cash Prizes

On December 3, twelve teams of creative, enterprising, young innovators pitched their business ideas and shared more than $10,000 in prize money during the University of Massachusetts Innovation Challenge Executive Summary & Elevator Pitch Competition. Building on previously submitted written materials, each team leader presented a two-minute pitch to a panel of judges from the private sector with wide-ranging expertise in creating new ventures. After hearing from all 12 teams, the judges deliberated and announced the awardees: innovation/announcements/judges-award-10000. Since 2005, the UMass Innovation Challenge has provided over $500,000 in awards to 69 different student-led teams.

Read more »
Corporate Partnership Gives Your Company an Insider’s Advantage Recruiting Engineering Students

Organizations that recruit UMass Amherst engineers often ask us about ways to improve their visibility and recruitment efforts on campus. The answer is through a $5,000 Corporate Partnership, which offers your company an insider’s jump on recruiting our best and brightest students. It’s like having several number-one picks in a Major League draft! The Engineering Career and Student Development Center offers a unique opportunity for your organization to strengthen its status on campus, while also supporting the professional development of potential future employees. The Corporate Partnership Program gives companies multiple insider resources to promote their brand and to develop lasting relationships with students, faculty, and the Engineering Career Center staff while on the UMass Amherst campus.

Read more »
Chait Featured on Research Next

The research of Mechanical and Industrial Engineering Professor Yossi Chait and his colleagues was recently featured on the UMass Research Next website in an article entitled “Patient Protocol: Improving treatment outcomes for dialysis patients.” Chait, a feedback systems engineer, is part of a multidisciplinary team that has been approved by an institutional review board to begin clinical testing of a groundbreaking new protocol for administering a key drug for managing patients in the final stage of kidney disease. “We are developing protocols for patients who have kidney disease and are undergoing dialysis and need precise, effective doses of recombinant human erythropoietin hormone,” says Chait. The hormone, also known as EPO, manages the production of red blood cells, which, among other things, controls anemia. Read the article: http://www.umass.edu/researchnext/patient-protocol.

Read more »